Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer
| Autor: | Funeng Jiang, Ming Xi, Wei Hua, Ru-Jun Mo, Hong-Wei Luo, Wei-de Zhong, Yueping Wan, Yangjia Zhuo, Yulin Zhou, Zhao-Chang Zen, Yuan-Ling Liu, Hui-Chan He, Song Wan |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology endocrine system Cancer Research medicine.medical_specialty Adolescent Kaplan-Meier Estimate Young Adult 03 medical and health sciences 0302 clinical medicine stomatognathic system Renal cell carcinoma Internal medicine Biomarkers Tumor medicine Carcinoma Humans Penile cancer Clinical significance RNA Messenger Young adult Child Carcinoma Renal Cell Penile Neoplasms Aged Neoplasm Staging Aged 80 and over Bladder cancer business.industry Cancer SOX9 Transcription Factor Hematology Middle Aged Prognosis medicine.disease Immunohistochemistry Kidney Neoplasms 030104 developmental biology Urinary Bladder Neoplasms Tissue Array Analysis Child Preschool 030220 oncology & carcinogenesis embryonic structures Female business |
| Zdroj: | Oncology Research and Treatment. 40:15-20 |
| ISSN: | 2296-5262 2296-5270 |
| Popis: | Background: Novel molecular markers are important diagnostic tools for the assessment of cancer progression and evaluation of effectiveness of the treatment. SOX9, a key regulator of developmental processes, is overexpressed in various neoplasms, such as prostate, breast, and colorectal cancers. However, the utilization of SOX9 as a biomarker for other urological cancers has not yet been investigated. Methods: In the present study, paired patient tissue microarrays were analyzed by immunohistochemistry, and the SOX9 protein expression was quantitated as immunoreactive scores in patients with renal cell carcinoma (RCC), bladder cancer (BCa), and penile cancer (PC). Results: In comparison with normal tissues, SOX9 protein expression was significantly upregulated in RCC (p < 0.001) and BCa (p < 0.001), and significantly correlated with the advanced pathological grade (RCC: p = 0.023) and clinical stage (RCC: p = 0.022 and BCa: p = 0.046) of patients. Based on the mRNA level in the TCGA dataset, SOX9 was upregulated in RCC with gender (p = 0.027), advanced pathological grade (p = 0.003) and advanced clinical stage (p = 0.001). Kaplan-Meier survival curves revealed that RCC patients with high SOX9 levels had shorter survival (p < 0.001). Further, high SOX9 expression was an independent prognostic factor for RCC patients (hazard ratio 0.056, 95% confidence interval 0.607-1.184; p < 0.001). Conclusion: These findings suggest that SOX9 may play an important role in tumor progression of RCC and BCa and it may be used as a biomarker of this malignancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|